Domino Data Lab and EPAM Systems have unveiled a strategic partnership aimed at revolutionizing AI adoption within the pharmaceutical and life sciences sectors. This collaboration, announced recently, seeks to transition AI projects from experimental stages into validated production environments, addressing critical challenges faced by life sciences companies.
What Happened
Domino Data Lab, known for its enterprise AI platform, has joined forces with EPAM Systems, a leader in engineering and life sciences expertise, to facilitate the deployment of GxP-validated AI models and governed analytics. The partnership is designed to cater to various stages of the biopharma lifecycle, including drug discovery, target identification, statistical computing, and real-world evidence analysis.
Life sciences companies are increasingly investing in artificial intelligence to enhance their research and development processes. However, scaling these projects across an entire enterprise can be challenging due to fragmented legacy systems, GxP revalidation requirements, and governance issues. Domino's platform aims to bridge these gaps, while EPAM offers specialized engineering capabilities to integrate AI technologies into existing IT environments seamlessly.
Dedicated engineering teams from both companies will work directly with customers to accelerate implementation timelines, modernize legacy code, and maintain compliance across diverse technology landscapes. For example, in drug discovery and target identification, AI agents, large language models, and machine learning pipelines can be deployed against large-scale genomic datasets to improve candidate selection.
What This Means for Your Business
For AECM professionals and government contractors involved in the life sciences sector, this partnership presents significant opportunities for procurement and contracting. The collaboration between Domino and EPAM can streamline AI deployment, offering a competitive edge by reducing the time required for regulatory submissions while ensuring compliance with stringent governance controls.
The initiative also highlights potential federal funding opportunities for companies looking to innovate in AI-driven drug discovery and development. By modernizing statistical computing environments and standardizing large datasets, the partnership could lead to cost efficiencies and improved return on investment for enterprises operating in highly regulated industries.
What US Operators Should Watch
Decision-makers should track the progress of this partnership, particularly the deployment timelines and the impact on regulatory submission processes. As AI continues to reshape the life sciences landscape, staying informed about developments in AI governance and compliance requirements is crucial. Companies should also monitor potential bid opportunities arising from this collaboration, as it may influence future procurement strategies and partnerships.
Source: https://pulse2.com/domino-data-lab-and-epam-partner-to-accelerate-ai-adoption-in-life-sciences/
Partner Insight · VisioneerIT
The partnership between Domino Data Lab and EPAM Systems highlights the importance of modernizing legacy systems to facilitate AI adoption in the life sciences sector. VisioneerIT specializes in software engineering and digital modernization, ensuring that enterprises can effectively integrate new technologies while maintaining compliance and efficiency.
Explore VisioneerIT Cybersecurity →
Is your firm ready for what’s next?
VisioneerIT helps AECM and government contractors modernize operations, achieve compliance, and implement AI.
Explore VisioneerIT Solutions →
